NCT07300293 Lactic Acidosis and Prior Metformin Treatment
| NCT ID | NCT07300293 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Strasbourg, France |
| Condition | Type 2 Diabetes |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-11-06 |
| Primary Completion | 2026-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2024-11-06 with a primary completion date of 2026-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Metformin is a drug frequently prescribed to patients with type 2 diabetes. Furthermore, diabetes can lead to micro- and macrovascular complications that may cause chronic organ failure. The presence of diabetes also increases the risk of infections. All of these factors contribute to the frequent admission of patients to the ICU who have been receiving metformin treatment in the preceding days. Acute renal failure, which is also frequently observed upon admission to the ICU, increases the risk of metformin overdose. In cases of overdose, metformin acts on several metabolic pathways that can lead to or even accelerate metabolic acidosis, sometimes severe. However, the impact on prognosis is controversial. The role of metformin in lactic acidosis in patients treated for acute illness may be underestimated in routine practice. This study aims to investigate the impact of prior metformin treatment on ICU survival in patients admitted to the ICU with severe lactic acidosis.
Eligibility Criteria
Inclusion Criteria: * Adult patient (≥18 years) * Admitted to the intensive care unit of Hautepierre Hospital - Strasbourg University Hospital between January 1, 2014, and December 31, 2023 * Having experienced lactic acidosis (pH \<7.35 and lactate level ≥5 mmol/L) within the first 24 hours of hospitalization. Exclusion Criteria: * Patient without arterial blood gas measurements during the first 24 hours of admission * whose background treatment is unknown and could not be determined * for whom a limitation of active therapies was implemented before or during the first 24 hours of hospitalization
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07300293 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Type 2 Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07300293 currently recruiting?
Yes, NCT07300293 is actively recruiting participants. Contact the research team at vincent.castelain@chru-strasbourg.fr for enrollment information.
Where is the NCT07300293 trial being conducted?
This trial is being conducted at Strasbourg, France.
Who is sponsoring the NCT07300293 clinical trial?
NCT07300293 is sponsored by University Hospital, Strasbourg, France. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.